Scopus BioPharma (NASDAQ:SCPS – Get Free Report) is projected to issue its resultson Wednesday, September 2nd. Analysts expect Scopus BioPharma to announce earnings of ($0.22) per share for the quarter.
Scopus BioPharma Price Performance
Shares of Scopus BioPharma stock opened at $0.00 on Tuesday. Scopus BioPharma has a twelve month low of $0.00 and a twelve month high of $0.01.
About Scopus BioPharma
Scopus BioPharma, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for central nervous system disorders. The company’s research efforts are aimed at addressing unmet medical needs in neuropathic pain, migraine and mood disorders by leveraging proprietary small-molecule platforms designed to modulate key neural pathways.
The company’s product pipeline comprises both clinical- and preclinical-stage candidates. Its lead programs include small-molecule compounds intended to provide relief in patients suffering from chronic neuropathic pain and episodic migraine.
Read More
- Five stocks we like better than Scopus BioPharma
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Scopus BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scopus BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
